New wonder drug to fight against heart attacks and cancer : NEJM Anjali Nimesh Nimesh29 Aug 2017 11:30 AM ISTA new wonder drug claimed to be biggest breakthrough in fight against heart attacks and cancer has been identified. The drug supposed to reduce the...
CANTOS identifies method to predict patients likely to benefit most with Canakinumab Anjali Nimesh Nimesh19 Nov 2017 7:10 PM ISTA new analysis seeks to answer the question of which patients are likely to gain the greatest cardiovascular benefit when treated with the...
Canakinumab FAILS to slow progress of prediabetes to diabetes : CANTOS Anjali Nimesh Nimesh16 March 2018 7:30 PM ISTCanakinumab is designed to disable interleukin-1 beta, a protein that plays a role in inflammation. The drug is approved for several autoimmune...
Increased hsCRP an indicator for residual risk after MI Dr. Kamal Kant Kohli Kohli2 April 2018 7:31 PM ISTThe data in CANTOS supported the inflammatory hypothesis of atherothrombosis but it remains uncertain which patients benefit the most from...
Anti-inflammatory drugs not yet for Atherosclerosis-ESC Consensus statement Dr. Kamal Kant Kohli Kohli14 May 2018 8:00 PM ISTEuropean Society of Cardiology (ESC) has released its latest consensus statement on inflammation in atherosclerosis which has been published in the...
Canakinumab reduces gout flares by more than half in atherosclerosis19 Vinay Singh singh4 July 2018 7:10 PM ISTCanakinumab significantly reduced the rate of gout by more than half among patients with atherosclerosis, according to the findings of the research...
Canakinumab not for heart attack prevention : FDA Vinay Singh singh21 Oct 2018 8:10 PM ISTThe U.S Food and Drug Administration has rejected to approve canakinumab for cardiovascular risk reduction, according to the Swiss drugmaker Novartis....
Refusal to canakinumab for secondary prevention -- Treatment of residual risk faces a roadblock Medha Baranwal Baranwal7 March 2019 8:28 PM ISTThe fight against the residual cardiovascular risk after myocardial infarction by targeting inflammation by anti-inflammatory drug faces a roadblock....
Quarterly Canakinumab reduces risk for gout Flares-Trial Report Vinay Singh singh23 Sept 2018 7:20 PM ISTQuarterly administration of canakinumab is linked to a significant reduction in risk for gout attacks without any change in serum uric acid levels,...
